Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
LY4178256 · 1 trial · 1 indication
A summary of SAEs and other non-serious adverse events (AEs), regardless of causality, will be reported in the Adverse Events module
A summary of SAEs and other non-serious adverse events (AEs), regardless of causality, will be reported in the Adverse Events module
| Arm | Type | Description |
|---|---|---|
| LY4178256 Part A: Single-Ascending Dose (SAD) (Cohorts 1-6b) | EXPERIMENTAL | LY4178256 or Placebo administered Intravenously (IV) |
| LY4178256 Part B: Multiple Ascending Dose (MAD) (Cohorts 1-3) | EXPERIMENTAL | LY4178256 or Placebo administered IV |
| Name | Type | Description |
|---|---|---|
| LY4178256 | DRUG | Administered intravenously (IV) |
| Placebo | DRUG | Administered IV |
Inclusion Criteria: * Are overtly healthy as determined by medical evaluation including medical history, physical examination, and other screening procedures. * Have a body mass index within the range of 19.0 to 32.0 kilograms per square meter (kg/m²) * Individuals assigned male at birth willing to...
LY4178256 is an investigational small molecule being developed by Eli Lilly and Company. It is currently in Phase 1 clinical development, with a single recruiting study in healthy adult volunteers. No therapeutic indication for LY4178256 has been disclosed, so its intended use has not been publicly announced.
LY4178256 is being developed by Eli Lilly and Company, which trades on the New York Stock Exchange under the ticker LLY. Lilly is the sponsor of the Phase 1 study evaluating the compound in healthy participants.
LY4178256 is in Phase 1 clinical development. It has one active, recruiting trial and no completed trials. Because it remains investigational, LY4178256 has not been approved by the FDA for any indication.
LY4178256 is being studied in one Phase 1 trial, NCT07698210, titled A Study of LY4178256 in Healthy Participants. The trial is recruiting 88 healthy adult volunteers in the United States. It is randomized, double-blind, and controlled, and is open to participants 18 years and older of all sexes.
Yes. The Phase 1 trial of LY4178256, NCT07698210, enrolls healthy volunteers rather than patients with a specific disease. The study is recruiting 88 participants aged 18 years and older in the United States, and it is randomized, double-blind, and controlled.